Tau imaging: early progress and future directions

  title={Tau imaging: early progress and future directions},
  author={Victor L. Villemagne and Michelle T. Fodero-Tavoletti and Colin L. Masters and Christopher C. Rowe},
  journal={The Lancet Neurology},

Figures from this paper

Untangling tau imaging

Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies

The development of tau ligands for imaging studies will be helpful for differential diagnosis and for the development of therapeutic treatments for tauopathies including Alzheimer’s disease.

Tau PET in Neurodegenerative Diseases Manifesting Dementia

Recent progress in the development of tau-selective PET tracers and clinical PET studies using these tracers are discussed.

In Vivo Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line

The utilities of PET, MRI, and fluorescence imaging for evaluating the disease progression of tauopathy are discussed and in vivo studies on a mouse model of t Tauopathy will provide significant insight into the translational research of neurodegenerative diseases.

Tau PET imaging: present and future directions

Recent findings on the most promising tau PET tracers to date are summarized, what has been learnt is discussed, and some suggestions for the next steps that need to be achieved in a near future are offered.

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions

How in vivo brain imaging of Aβ pathology has revolutionized the evaluation of patients with clinical AD by providing robust and reproducible statements of global or regional brain Aβ burden and enabling the monitoring of disease progression is described.

Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease

PET imaging of tau and Ab in a cohort of cognitively normal older adults and those with mild AD support models of AD where tau pathology closely tracks changes in brain function that are responsible for the onset of early symptoms in AD.

Tau imaging in neurodegenerative diseases

The role of aggregated tau in tauopathies, the challenges posed in developing selective tau ligands as biomarkers, the state of development in tAU tracers, and the new clinical information that has been uncovered are discussed, as well as the opportunities for improving diagnosis and designing clinical trials in the future.



The challenges of tau imaging

Development of a tau imaging tracer will enable researchers to noninvasively examine the degree and extent of tau pathology in the brain, quantify changes in tau deposition over time, evaluate its relation to cognition and assess the efficacy of anti-tau therapy.

In vivo tau imaging: Obstacles and progress

The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias

The observations suggest that Aβ deposition is not part of normal ageing, supporting the hypothesis that A β deposition occurs well before the onset of symptoms and is likely to represent preclinical AD.

Neuropathological alterations in Alzheimer disease.

Postmortem studies have enabled the staging of the progression of both amyloid and tangle pathologies, and the development of diagnostic criteria that are now used worldwide, and these cross-sectional neuropathological data have been largely validated by longitudinal in vivo studies using modern imaging biomarkers such as amyloids PET and volumetric MRI.

Neurodegenerative tauopathies.

Emerging data support the hypothesis that different tau gene mutations are pathogenic because they impair tau functions, promote tau fibrillization, or perturb tAU gene splicing, thereby leading to formation of biochemically and structurally distinct aggregates of tau.

Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

The results of this study suggest that 18F-THK523 selectively binds to paired helical filament tau in AD brains but does not bind to tau lesions in non-AD tauopathies, or to α-synuclein in PD brains.

In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease

18F-THK523 does not bind to Aβ in vivo, while following the known distribution of paired helical filaments (PHF)-tau in the brain, and selectively binds to tau in AD patients.